149 related articles for article (PubMed ID: 22298606)
1. Rosiglitazone, myocardial ischemic risk, and recent regulatory actions.
Bourg CA; Phillips BB
Ann Pharmacother; 2012 Feb; 46(2):282-9. PubMed ID: 22298606
[TBL] [Abstract][Full Text] [Related]
2. The rosiglitazone decision process at FDA and EMA. What should we learn?
Pouwels KB; van Grootheest K
Int J Risk Saf Med; 2012; 24(2):73-80. PubMed ID: 22751189
[TBL] [Abstract][Full Text] [Related]
3. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
Dahabreh IJ; Economopoulos K
Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
[TBL] [Abstract][Full Text] [Related]
5. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
6. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
7. Clinical consequences of disseminating the rosiglitazone FDA safety warning.
Orrico KB; Lin JK; Wei A; Yue H
Am J Manag Care; 2010 May; 16(5):e111-6. PubMed ID: 20455636
[TBL] [Abstract][Full Text] [Related]
8. Results of a reevaluation of cardiovascular outcomes in the RECORD trial.
Mahaffey KW; Hafley G; Dickerson S; Burns S; Tourt-Uhlig S; White J; Newby LK; Komajda M; McMurray J; Bigelow R; Home PD; Lopes RD
Am Heart J; 2013 Aug; 166(2):240-249.e1. PubMed ID: 23895806
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
Nagajothi N; Adigopula S; Balamuthusamy S; Velazquez-Cecena JL; Raghunathan K; Khraisat A; Singh S; Molnar J; Khosla S; Benatar D
Am J Ther; 2008; 15(6):506-11. PubMed ID: 19127132
[TBL] [Abstract][Full Text] [Related]
10. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
Cobitz A; Zambanini A; Sowell M; Heise M; Louridas B; McMorn S; Semigran M; Koch G
Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):769-81. PubMed ID: 18613278
[TBL] [Abstract][Full Text] [Related]
11. The rough road for rosiglitazone.
Goldfine AB
Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):113-7. PubMed ID: 18316944
[TBL] [Abstract][Full Text] [Related]
12. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.
Starner CI; Schafer JA; Heaton AH; Gleason PP
J Manag Care Pharm; 2008; 14(6):523-31. PubMed ID: 18693776
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular risk of rosiglitazone: another perspective.
Waksman JC
J Pharm Pharmacol; 2008 Dec; 60(12):1573-82. PubMed ID: 19000361
[TBL] [Abstract][Full Text] [Related]
15. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.
Mannucci E; Monami M; Di Bari M; Lamanna C; Gori F; Gensini GF; Marchionni N
Int J Cardiol; 2010 Aug; 143(2):135-40. PubMed ID: 19328563
[TBL] [Abstract][Full Text] [Related]
16. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
Singh S; Loke YK; Furberg CD
JAMA; 2007 Sep; 298(10):1189-95. PubMed ID: 17848653
[TBL] [Abstract][Full Text] [Related]
17. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct.
Lopes RD; Dickerson S; Hafley G; Burns S; Tourt-Uhlig S; White J; Newby LK; Komajda M; McMurray J; Bigelow R; Home PD; Mahaffey KW
Am Heart J; 2013 Aug; 166(2):208-216.e28. PubMed ID: 23895802
[TBL] [Abstract][Full Text] [Related]
18. Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings.
Jain R; Mullins CD; Lee H; Wong W
Res Social Adm Pharm; 2012; 8(1):47-59. PubMed ID: 21733760
[TBL] [Abstract][Full Text] [Related]
19. Revisiting the rosiglitazone story--lessons learned.
Rosen CJ
N Engl J Med; 2010 Aug; 363(9):803-6. PubMed ID: 20660395
[No Abstract] [Full Text] [Related]
20. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.
Winkelmayer WC; Setoguchi S; Levin R; Solomon DH
Arch Intern Med; 2008 Nov; 168(21):2368-75. PubMed ID: 19029503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
